Attached files
| file | filename |
|---|---|
| EX-32 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Monopar Therapeutics | exhibit32-1.htm |
| EX-31 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeutics | exhibit31-2.htm |
| EX-31 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeutics | exhibit31-1.htm |
| EX-21 - SUBSIDIARIES OF THE REGISTRANT - Monopar Therapeutics | exhibit21-1.htm |
| EX-10 - MATERIAL CONTRACTS - Monopar Therapeutics | exhibit10_12prx2019consag.htm |
| EX-10 - MATERIAL CONTRACTS - Monopar Therapeutics | exhibit10_11iso.htm |
| EX-10 - MATERIAL CONTRACTS - Monopar Therapeutics | exhibit10_10nq.htm |
| EX-4 - INSTRUMENTS DEFINING THE RIGHTS OF SECURITY HOLDERS, INCLUDING INDENTURES INSTRU - Monopar Therapeutics | exhibit4-1.htm |
| 10-K - PRIMARY DOCUMENT - Monopar Therapeutics | mnpr_10k2019.htm |
Exhibit
23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We
hereby consent to the incorporation by reference in the
Registration Statements on Form S-1 (333-233303), on Form S-3
(333-235791) and on Form S-8 (333-235790) of our report dated March
27, 2020, relating to the consolidated financial statements of
Monopar Therapeutics Inc. as of December 31, 2019, which appears in
this Annual Report on Form 10-K.
We also
consent to the reference to us under the caption
“Experts” in such Registration Statements.
/s/ BPM
LLP
San
Francisco, California
March
27, 2020